Introduction {#sec1}
============

Functional modification of proteins can be achieved in a wide variety of ways. Early generation approaches, entailing the reaction with amino or thiol groups of amino acid side chains,^[@ref1]−[@ref3]^ are effective and facile but in most cases lack selectivity due to relatively high natural abundance of lysines and cysteines in proteins.^[@ref3]^ Other methods involving conjugation to tyrosine, histidine, or tryptophan side chains, or to the N-terminus of proteins have also been developed.^[@ref2]^ As an alternative to native proteins, full control of regioselectivity can be achieved by introduction of a non-natural amino acid containing a functional handle such as an azide, a ketone or an *ortho*-aminophenol but often at the expense of protein expression yields.^[@ref4]−[@ref6]^ Site-specific conjugation can also be achieved through enzymatic means, as, for example, with sortase-mediated conjugation, formyl-generating enzyme (FGE), tubulin tyrosine ligase, or activation of dihydrotetrazines by oxidation for tetrazine--TCO ligation via horseradish peroxidase or a photocatalytic agent.^[@ref7]−[@ref10]^

Tyrosine residues show promise as selective conjugation sites, as the relative hydrophobicity of tyrosine combined with the tendency of π--π stacking of the aromatic rings results in the limited exposure of tyrosine residues on the periphery of proteins, resulting in generally low accessibility.^[@ref11],[@ref12]^ As a consequence, reactive small molecules may conjugate to tyrosines for less-selective conjugation,^[@ref13]−[@ref15]^ while more-exposed tyrosines can allow for a wide variety of enzymatic reactions.^[@ref12],[@ref16]−[@ref20]^ For example, exposed tyrosine residues can be oxidized by mushroom tyrosinase to generate a 1,2-quinone, which can undergo nucleophilic attack by amines or thiols from the side chains of lysine, histidine, or cysteine.^[@ref21]−[@ref23]^

We recently showed that a 1,2-quinone undergoes fast strain-promoted oxidation-controlled quinone--alkyne cycloaddition (SPOCQ) with bicyclo\[6.1.0\]nonyne (BCN).^[@ref24]−[@ref26]^ Here, we report that SPOCQ finds useful application in protein labeling via in situ generation of a quinone by oxidation under the action of mushroom tyrosinase (mTyr). We demonstrate that fast and complete C-terminal labeling of proteins, including an enzyme and a monoclonal antibody, can be readily achieved. The potential usefulness of the SPOCQ labeling approach is exemplified by fully controlled, site-specific generation of an antibody-drug conjugate based on anti-influenza AT1002 and the highly potent tubulin binder monomethyl auristatin F (MMAF).

Results and Discussion {#sec2}
======================

Laminarinase A {#sec2.1}
--------------

Given the inaccessibility of native tyrosine residues by mTyr,^[@ref11],[@ref12]^ it was envisioned that an exposed tyrosine required installation in a protein of interest by means of a short spacer. Thus, tetra-glycyltyrosine (G~4~Y) was genetically fused to the C-terminus of a model protein laminarinase A (LamA), a hyperthermostable endo-β-1,3-glucanase from *Pyrococcus furiosus*, which contained an N-terminal His tag for purification.^[@ref16],[@ref27]^ Modifications were achieved via site-directed mutagenesis and expression in *Escherichia coli* (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf) section 7), resulting in a C-terminal G~4~Y fusion (LamA--G~4~Y, here referred to as Y-tag).

Purified LamA--G~4~Y was subjected to oxidation by catalytic mTyr (7.5 mol %) to generate the intermediate 1,2-quinone, anticipated to undergo in situ SPOCQ with BCN-modified lissamine **1**, present in 4-fold excess ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Gratifyingly, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis indicated the conversion of LamA--G~4~Y into the labeled product after incubation at 37 °C for 30 min with an apparent high conversion ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). Negative controls indicated the specificity of conjugation: no fluorescently labeled LamA was detected in the absence of mTyr (lane C). Incubation with mTyr without **1** led solely to an unidentified band (lane B), most likely originating from aspecific intramolecular nucleophilic attack of an amino acid residue (e.g., Lys and His) to the generated quinone, causing it to appear at the expected position.^[@ref22],[@ref23]^ No fluorescence was detected when SPOCQ was performed with wt-LamA (lane I), which implies that only the newly introduced C-terminal tyrosine is oxidized and undergoes SPOCQ. Mass spectrometry (MS) analysis of the SPOCQ reaction show a main product corresponding to the product resulting from oxidation and cycloaddition of **1** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B,C), with a deviation of ±1 Da. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B displays MS profile of LamA--G~4~Y prior to oxidation, in agreement with the calculated mass, whereas [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C exhibits LamA--G~4~Y after oxidation and SPOCQ. The desired product was identified as a peak with molecular weight 32647 Da, indicating an increase of 880 Da (calculated 879 Da) from oxidation of the tyrosine and subsequent conjugation with **1**. The oxidized LamA, which underwent aspecific conjugation by a nucleophilic amino acid residue addition was also clearly detected on MS with a mass increase of approximately 13 Da. Further experiments showed that conjugation via SPOCQ could also be performed at 4 and 16 °C and ambient temperature with no observable difference in efficiency ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf)).

![SPOCQ labeling of G4Y-tagged laminarinase A by reaction of BCN-modified reagent 1 with in situ generated 1,2-quinone. Typical reaction conditions: LamA (1.0 mg/mL), mTyr (0.3 mg/mL), and **1** (4 equiv) in 50 mM potassium phosphate buffer pH 7.3, containing 135 mM NaCl and 10% DMSO as cosolvent.](bc-2017-000465_0001){#fig1}

![(A) SDS-PAGE analysis of SPOCQ on LamA--G~4~Y and wt-LamA. (B) MS profile of LamA--G~4~Y. (C) MS profile of LamA--G~4~Y after SPOCQ with **1**.](bc-2017-000465_0002){#fig2}

Trastuzumab {#sec2.2}
-----------

Having successfully demonstrated the suitability of SPOCQ for C-terminal protein conjugation, its usefulness for site-specific modification of monoclonal antibodies was investigated next. Trastuzumab with genetically engineered tetra-glycyltyrosine on both light chains (Tras\[LC\]G~4~Y) was transiently expressed in CHO-K1 and purified by protein A affinity chromatography ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf) section 8). Next, Tras\[LC\]G~4~Y was subjected to identical conditions for conjugation with **1** (5 equiv) by SPOCQ at 16 °C as described for LamA. As expected, SDS-PAGE analysis indicated exclusive conversion of Tras\[LC\]G~4~Y upon incubation with both **1** and mTyr ([Figure S3A](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf)), while no reaction was detected on either chain for native trastuzumab under identical conditions. Mass spectrometric analysis confirmed successful addition of **1** via SPOCQ ([Figure S3 B,C](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf)). It is worth pointing out that the reaction also proceeded at 4 °C, albeit much slower, but to our surprise, no fluorescent protein could be detected at higher temperature (37 °C), possibly via competing intramolecular reaction of the intermediate quinone with nearby lysine or histidine side chains ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf)).

AT1002 {#sec2.3}
------

To further assess the applicability of SPOCQ for site-specific modification of monoclonal antibodies, we modified AT1002, a potent anti-influenza antibody, with a C-terminal G~4~Y tag ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf) section 9).^[@ref28]^ To this end, AT1002 with a sortase tag residing on the C-terminus of each light chain was employed to obtain a C-terminally fused G~4~Y (AT1002\[LC\]G~4~Y). Of relevance, the obtained AT1002\[LC\]G~4~Y possesses a longer C-terminally fused tag (-G~4~SLPETG~4~Y) compared to Tras\[LC\]G~4~Y, which was anticipated to contribute favorably with regard to accessibility of the tyrosine by mTyr.^[@ref29]^ SPOCQ was attempted on AT1002\[LC\]G~4~Y under identical conditions compared to Tras\[LC\]G~4~Y, after which SDS-PAGE analysis demonstrated similar conjugation selectivity with high conversion: only fluorescence on the light chain was detected when reacted with mTyr and **1** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Interestingly, fluorescence of the labeled AT1002 seems more intense than that of trastuzumab under identical condition, which was taken a confirmation that labeling to the light chain with a short spacer may be encumbered by less steric accessibility. Additionally, a protein band corresponding to the conjugated product was observed by SDS-PAGE analysis upon Coomassie staining, indicating a significantly higher conversion for AT1002\[LC\]G~4~Y. MS analysis confirmed SPOCQ on AT1002 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C,D). As with trastuzumab, some nonlabeled material was still present, which may indicate that also in this case a fraction of the formed quinone reacts with lysine or histidine residues.

![(A) Schematic representation of G~4~Y-tagged antibodies. (B) SDS-PAGE analysis of SPOCQ on AT1002\[LC\]G~4~Y and wt-AT1002. (C) MS profile of AT1002\[LC\]G~4~Y (light chain only). (D) MS spectrum of AT1002\[LC\]G~4~Y after SPOCQ with **1**. (E) MS profile of AT1002\[LC\]G~4~Y after SPOCQ with **2**.](bc-2017-000465_0003){#fig3}

Our newly developed conjugation method was envisioned to be suitable as a site-specific approach to access antibody--drug conjugates (ADCs). These are a class of promising chemotherapeutics used for targeted treatment of tumors by combining the high cytotoxicity of a drug such as monomethyl auristatin E (MMAE) or maytansine with an antibody that has high binding affinity to the tumor cell of choice.^[@ref30]^ The ability of ADCs to bring highly toxic compounds selectively to the tumor cells allows the treatment of cancers while reducing the effect on healthy tissue as with traditional chemotherapies, which has led to the recent market approval of Adcetris (for the treatment of non-Hodgkin lymphoma and anaplastic large-cell lymphoma) and Kadcyla (for treatment of HER2-positive breast cancer).^[@ref31],[@ref32]^ To this end, AT1002\[LC\]G~4~Y was subjected to BCN-monomethyl auristatin F conjugate (BCN-MMAF, **2**) after oxidation by mTyr under identical conditions as before, with the exception that DMF was used as cosolvent instead of DMSO. Much to our satisfaction, the desired ADC was seamlessly obtained, as indicated by the expected mass increase of 1459 Da ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E), which corresponds to oxidation followed by cycloaddition (SPOCQ) with **2**.

Conclusions {#sec3}
===========

We have successfully developed a site-specific bioconjugation method based on the in situ enzymatic oxidation of tyrosine by mushroom tyrosinase. Various BCN derivatives were successfully conjugated to C-terminal, oxidized tyrosine residues via SPOCQ. This cycloaddition occurs quickly, selectively, and under physiological conditions on a variety of proteins. Extensive optimization of reaction conditions is anticipated to allow fully selective and quantitative conversion. Research along those lines is currently ongoing in our laboratories. We envision that SPOCQ on tyrosine residues can be a valuable tool to create more unique, orthogonal conjugation possibilities for a wide variety of protein modifications, including the preparation of next-generation, site-specifically generated antibody--drug conjugates.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.bioconjchem.7b00046](http://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.7b00046).Additional method and material details, SPOCQ and expression details, gene and protein sequences, a schematic view of the reaction and corresponding mass values, and MS data. ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.7b00046/suppl_file/bc7b00046_si_001.pdf))
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